PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces Industry’s First FRET-Based – SensoLyte® Green Elastase Assay Kits - AnaSpec, Eurogentec Group is pleased to introduce the SensoLyte® Green Elastase Assay Kit - the first FRET-based Elastase activity assay kit in the industry
AnaSpec Introduces Industry’s First FRET-Based – SensoLyte® Green Elastase Assay Kits

 

NewswireToday - /newswire/ - Fremont, CA, United States, 2011/02/02 - AnaSpec, Eurogentec Group is pleased to introduce the SensoLyte® Green Elastase Assay Kit - the first FRET-based Elastase activity assay kit in the industry.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

This kit employs a natural substrate, elastin that is labeled with the 5-FAM fluorophore and the QXL™ 520 quencher. Proteolytic cleavage of labeled elastin separates the donor from the quencher and yields brightly green fluorescence, which can be continuously monitored at excitation/emission (Ex/Em) = 488 nm/520 nm. Increase in fluorescence intensity is directly proportional to elastase activity. The kit can be used to continuously measure the kinetics of elastase activity. As well, this highly sensitive kit is homogeneous – it does not require any separation steps.

Elastases catalyze the hydrolysis of elastin, the chief constituent of elastic fibers that together with collagen determines the mechanical properties of connective tissue. Elastases have many other natural substrates these include proteoglycans, collagens and fibronectin.1-4 Implicated in many diseases such as pulmonary emphysema, cystic fibrosis, infections, inflammation and atherosclerosis, elastases are considered important drug targets.5

AnaSpec, Eurogentec Group also provides another green emitting elastase assay, the SensoLyte® Rh110 Elastase Assay Kit. This assay uses a substrate that is labeled with a fluorogenic dye called Rh110 (rhodamine 110). Upon cleavage by elastase, the substrate generates free Rh110 fluorophore, which has a bright green fluorescence. Signal can be detected at Ex/Em =490/520 nm. The longer wavelength spectra and higher extinction coefficient of this kit and the SensoLyte® Green Elastase kits provide greater sensitivity and less interference from other reaction components.

References
1. Kafienah, W. et al. Biochem J. 330, 897 (1998).
2. Carlo, L. et al. J. Biol. Chem. 255, 12006 (1980).
3. Mainardi, CL. et al. J. Biol. Chem. 255, 5435 (1980).
4. McDonald, JA. et al. J. Biol. Chem. 255, 8848 (1980).
5. Bieth, JG. J. Soc. Biol. 195, 173 (2001).

About AnaSpec, Eurogentec Group
AnaSpec (anaspec.com), Eurogentec Group is a leading provider of integrated proteomics and genomics solutionsTM for worldwide life science research. As a subsidiary of Eurogentec, AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, oligonucleotides, and qPCRs. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces Industry’s First FRET-Based – SensoLyte® Green Elastase Assay Kits

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)